Abstract Body

Individuals with hepatitis C (HCV) represent a population who may benefit from PrEP, given overlapping risk factors and transmission networks of HCV and HIV. This analysis assesses the prevalence of PrEP indications among individuals with HCV and associations with PrEP awareness, access, and interest.

GRAVITY was an observational study for the collection of epidemiologic data from individuals with HCV and/or HIV, with the present analysis limited to HCV mono-infected patients. Participants were recruited from 7 sites in Washington DC and Baltimore. A drug use indication for PrEP was defined as injection drug use within 12 months and sharing of injecting equipment. A sexual indication for PrEP was defined as one of the following within 12 months: 1. >1 sexual partner and inconsistent condom use during anal or vaginal sex; 2. Transactional sex, defined as sex in exchange for drugs, money, or shelter; and/or 3. An HIV+ partner. Bivariate analysis assessed for associations between PrEP indications and PrEP awareness, access, and interest. Variables of significance were used to build a multivariable logistic regression model. Analyses were conducted using SAS version 9.3.

Among 314 HCV mono-infected participants, 109 (35%) had an indication for PrEP. 48 (15%) had a drug use indication alone, 40 (13%) had a sexual indication alone, and 21 (7%) had both drug use and sexual indications. 85 (27%) participants had heard of PrEP, 32 (10%) had been offered PrEP by a provider, 114 (38%) were interested in PrEP, and 6 (2%) were currently taking PrEP. On bivariate analysis, PrEP awareness was significantly associated with study site (p<0.0001), race (p=0.0003), age (p<0.0001), and sexual (p=0.0373) PrEP indication. However, on regression analysis, only study site remained significant (p<0.0001). On regression analysis, past offer of PrEP by a provider was associated with study site (p=0.0012), and PrEP interest was associated with study site and self-perception of HIV risk (p=0.0028; p<0.0001).

Though indications for PrEP were prevalent among individuals with HCV in this cohort, most patients were unaware of PrEP, had never been offered PrEP, and were not using PrEP. The significant association between study site and both PrEP awareness and provider offerings of PrEP suggest high variability in PrEP access by location of healthcare utilization. These data support the need for improved PrEP implementation among people with HCV at risk for HIV acquisition.